Cargando…

Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System

Objectives: Intraocular administration of vascular endothelial growth factor (VEGF) inhibitors may be associated with pregnancy loss. However, little is known about intraocular anti-VEGF therapy during pregnancy. Here, we conducted a pharmacovigilance study using a spontaneous reporting database to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakai, Takamasa, Mori, Chiyo, Ohtsu, Fumiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684212/ https://www.ncbi.nlm.nih.gov/pubmed/36438807 http://dx.doi.org/10.3389/fphar.2022.1063625

Ejemplares similares

Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases
por: Sakai, Takamasa, et al.
Publicado: (2021)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
por: Fang, Zhihong, et al.
Publicado: (2023)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

Visualization of Kinase Inhibition-Related Adverse Events Using the Japanese Adverse Drug Event Report Database
por: Mizuno, Takahito, et al.
Publicado: (2021)

Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)
por: Pera, Victor, et al.
Publicado: (2023)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis
por: Xue, Yifei, et al.
Publicado: (2023)

Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2019)

Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System
por: Barcelos, Flávia Campos, et al.
Publicado: (2019)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Anti-NMDA receptor encephalitis and vaccination: A disproportionality analysis
por: Martin, Salomé, et al.
Publicado: (2022)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances
por: Khouri, Charles, et al.
Publicado: (2021)

Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (Faers) Database
por: Kurian, Anitha, et al.
Publicado: (2018)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system
por: Wu, Ziyang, et al.
Publicado: (2022)

Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
por: Matsumoto, Kiyoka, et al.
Publicado: (2020)

Analysis of medication and prescription background risk factors contributing to oral medication administration errors by nurses: A case–control study
por: Suzuki, Ryohei, et al.
Publicado: (2022)

COVID-19 Vaccine-Associated Transient Global Amnesia: A Disproportionality Analysis of the WHO Safety Database
por: Merino, Diane, et al.
Publicado: (2022)

1407. Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
por: Timbrook, Tristan T, et al.
Publicado: (2018)

Early ascorbic acid administration prevents vascular endothelial cell damage in septic mice
por: Madokoro, Yutaro, et al.
Publicado: (2022)

Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity
por: Gao, Caifeng, et al.
Publicado: (2023)

Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System
por: Li, Xiaotong, et al.
Publicado: (2023)

Analysis of factors affecting pharmacists' ability to identify and solve problems
por: Watanabe, Keigo, et al.
Publicado: (2023)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis
por: Zhou, Yu, et al.
Publicado: (2022)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
por: Zhang, Ying, et al.
Publicado: (2023)

Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System
por: Huang, Liting, et al.
Publicado: (2021)

Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System
por: Yang, Renjun, et al.
Publicado: (2022)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
por: Wang, Jun, et al.
Publicado: (2023)

Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System
por: Wei, Chunyan, et al.
Publicado: (2023)

Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase
por: Noseda, Roberta, et al.
Publicado: (2021)

Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
por: Kong, Wenqiang, et al.
Publicado: (2023)

Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study
por: Campbell, Robert J, et al.
Publicado: (2012)

Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure
por: Nariani, Ashiyana, et al.
Publicado: (2016)

Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
por: Wei, Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s406hralde2hs3rddb2f66p65b